Austin Angelo

About the Author Austin Angelo


Analysts Offer Insights on Services Companies: Laboratory Corp (LH) and Spirit Airlines (SAVE)

There’s a lot to be optimistic about in the Services sector as 2 analysts just weighed in on Laboratory Corp (LH) and Spirit …

Okta Inc (OKTA) Receives a Buy from Oppenheimer

Oppenheimer analyst Shaul Eyal maintained a Buy rating on Okta Inc (OKTA) today and set a price target of $80. The company’s shares …

Oppenheimer Sticks to Their Buy Rating for Conatus Pharmaceuticals (CNAT)

Oppenheimer analyst Jay Olson maintained a Buy rating on Conatus Pharmaceuticals (CNAT) today and set a price target of $10. The company’s shares …

Healthequity (HQY) Gets a Hold Rating from Cantor Fitzgerald

Cantor Fitzgerald analyst Steven Halper reiterated a Hold rating on Healthequity (HQY) today and set a price target of $82. The company’s shares …

Cantor Fitzgerald Keeps Their Buy Rating on Viewray (VRAY)

Cantor Fitzgerald analyst Craig Bijou reiterated a Buy rating on Viewray (VRAY) today and set a price target of $13. The company’s shares …

ACADIA Pharmaceuticals Inc (ACAD) Receives a Buy from Cantor Fitzgerald

In a report released yesterday, Charles Duncan from Cantor Fitzgerald reiterated a Buy rating on ACADIA Pharmaceuticals Inc (ACAD), with a price target …

National Bank Keeps Their Buy Rating on Thomson Reuters (TRI)

In a new note to investors today, an analyst has provided a rating update for the Services sector company, Thomson Reuters (TRI). National …

GMP FirstEnergy Downgrades HIVE Blockchain Technologies Ltd (HIVE) to Hold

In a latest note to investors, a research analyst has provided a rating update for the HIVE Blockchain Technologies Ltd (HIVE). GMP FirstEnergy’s …

Thomson Reuters (TRI) Gets a Hold Rating from CIBC

Thomson Reuters (TRI), the Services sector company, was revisited by a Wall Street analyst yesterday. The company received a Hold rating from CIBC’s …

Cantor Fitzgerald Remains a Buy on Cytokinetics Inc (CYTK)

Cantor Fitzgerald analyst Charles Duncan maintained a Buy rating on Cytokinetics Inc (CYTK) today and set a price target of $14. The company’s …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts